Insider Purchases: Inside the Buy

Tag: Tim Buckley

Editorial illustration depicting a physician reviewing Pfizer's financial outlook alongside biotechnology imagery, DNA strands, oncology research, dividend metrics, insider buying indicators, and rising valuation charts.

💊 Pfizer (PFE): Why a Former Vanguard CEO Just Bought Nearly $1 Million of This 6.4% Dividend Stock

Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.

Read entire article

Tags: AlbertBourla, Biotech, buy or sell PFE, Deep Value, Dividend Investing, Dividend Stocks, FUNanc1al, GLP-1, Healthcare, Healthcare Stocks, HighDividend, Insider Buying, Insider Purchases, Long-Term Investing, MortimerBuckley, Oncology, PFE, Pfizer, Pharmaceuticals, Rare Diseases, risks buying PFE, Ronald Blaylock, Seagen, Tim Buckley, Vaccines, Value Investing, ValueInvesting, Vanguard, why buy PFE
Cartoon of Boeing jet preparing for takeoff while carrying heavy debt bags, with Tim Buckley as pilot and major institutions cheering.

Is Boeing Ready to Fly?

Boeing’s new director — ex-Vanguard CEO Tim Buckley — just bought nearly $500K of stock. With a $619B backlog and cash flow stabilizing, is this aerospace giant finally ready for liftoff… or more turbulence?

 

Read entire article

Tags: aerospace stocks, BA stock, Boeing, DIrector Buying, Director Insider Buying, Funanc1al, Funanc1al Contrarian Plays, Funanc1al for Investors, Funanc1al Insights, Funanc1al Investing, Funanc1al Turnaround Plays, Funanc1alAviation, Funanc1alEdge, Funanc1alFun, Funanc1alHumor, insider buying, institutional investors, investing insights, stock market, Tim Buckley, turnaround plays, Vanguard